Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (SMART)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04851873 |
Recruitment Status :
Completed
First Posted : April 21, 2021
Results First Posted : January 5, 2024
Last Update Posted : January 5, 2024
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Spinal Muscular Atrophy | Genetic: OAV101 | Phase 3 |
This was an open-label, single arm, multi-center study designed to evaluate the safety, tolerability and efficacy of OAV101 in participants with SMA who weigh ≥ 8.5 kg and ≤ 21 kg. The study aimed to enroll approximately 24 to 30 participants, with approximately 6 to 10 participants across each of 3 weight brackets (8.5 to 13 kg, >13 to 17 kg, >17 to 21 kg).
Eligible participants received a single administration of OAV101 at the approved dose of 1.1e14 vg/kg on Day 1 (Treatment period), and were followed for a period of 12 months.
Participants were admitted to the hospital on Day -1 for pre-treatment baseline procedures. After receiving OAV101 on Day 1, participants underwent in-patient safety monitoring over the next 48 hours, after which the participant could be discharged, based on Investigator judgment.
After study completion, eligible participants could enroll into a Long Term follow-up study to collect additional safety and efficacy data. (COAV101A12308 (NCT05335876) https://classic.clinicaltrials.gov/ct2/show/NCT05335876?term=COAV101A12308&draw=2&rank=1))
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Participants will receive a single administration of OAV101 |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase IIIb, Open-label, Single-arm, Single-dose, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Gene Replacement Therapy With Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) |
Actual Study Start Date : | September 8, 2021 |
Actual Primary Completion Date : | June 13, 2023 |
Actual Study Completion Date : | June 13, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: OAV101
Participants received a single IV dose administration of OAV101
|
Genetic: OAV101
Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes. |
- Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) by Weight Bracket [ Time Frame: Up to Month 12 ]An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study.
- Number of Participants With Important Identified and Important Potential Risks (Adverse Events of Special Interest (AESI)) by Risk Name and Weight Bracket [ Time Frame: Up to Month 12 ]
Important identified and important potential risks included the following AESIs: Hepatotoxicity, Thrombocytopenia, Cardiac adverse events, Dorsal root ganglia toxicity and Thrombotic microangiopathy.
These were assessed by the investigator.
- Summary of Participants Meeting Criteria for Potentially Clinically Significant Vital Sign Values by Weight Bracket - Systolic and Diastolic Blood Pressure [ Time Frame: 12 months ]
Change from baseline in vital signs measurements - systolic and diastolic blood pressure (mmHg).
Systolic Blood Pressure-Low:<=5th percentile of the age(Any Age), High:>=90th percentile of the age, gender, and height group (<18 yrs).
Diastolic Blood Pressure-High:>=90th percentile of the age, gender, and height group(<18 yrs).
- Change From Baseline in Vital Signs Measurements - Systolic Blood Pressure (mmHg) [ Time Frame: Baseline, Days 2 and 3, Weeks 1, 2, 3, 4, 6, 8, 10, 13, 26, 39 and 52 ]
- Change From Baseline in Vital Signs Measurements - Diastolic Blood Pressure (mmHg) [ Time Frame: Baseline, Days 2 and 3, Weeks 1, 2, 3, 4, 6, 8, 10, 13, 26, 39 and 52 ]
- Change From Baseline in Vital Signs Measurements - Respiratory Rate (Breaths/Min) [ Time Frame: Baseline, Days 2 and 3, Weeks 1, 2, 3, 4, 6, 8, 10, 13, 26, 39 and 52 ]Change from baseline in vital signs measurements - Respiratory Rate (breaths/min)
- Change From Baseline in Vital Signs Measurements - Pulse Rate (Beats/Min) [ Time Frame: Baseline, Days 2 and 3, Weeks 1, 2, 3, 4, 6, 8, 10, 13, 26, 39 and 52 ]Change from baseline in vital signs measurements - Pulse Rate (beats/min
- Summary of Participants Meeting Criteria for Potentially Clinically Significant Vital Sign Values by Weight Bracket - Temperature [ Time Frame: 12 months ]
Change from baseline in vital signs measurements - temperature (degrees Celsius)
Temperature-Low:<=35ºC(Any Age),High:>=38.4ºC(<18 yrs).
- Change From Baseline in Vital Signs Measurements - Temperature (Degrees Celsius) [ Time Frame: Baseline, Days 2 and 3, Weeks 1, 2, 3, 4, 6, 8, 10, 13, 26, 39 and 52 ]
- Change From Baseline in Vital Signs Measurements - Oxygen Saturation Level [ Time Frame: Baseline, Days 2 and 3, Weeks 1, 2, 3, 4, 6, 8, 10, 13, 26, 39 and 52 ]
Change from baseline in vital signs measurements - oxygen saturation level (%).
Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated+saturated) in the blood and then multiplied by 100.
- Achievement of Development Motor Milestones According to the Modified and Combined WHO-MGRS and Bayley Scale of Infant and Toddler Development. [ Time Frame: Baseline, Week 26 and Week 52 ]The World Health Organization-Multicentre Growth Reference Study (WHO-MGRS) and Bayley scale of Infant and Toddler Development was modified and combined into a single scale expressly for this study, to measure developmental motor milestones. These were assessed via the milestone checklist, formed of 10 yes/no questions with optional video documentation. The developmental milestones are: head control, sitting with support, sitting without support, sitting without support for 30 seconds, hands-and-knees crawling, pulls to stand, standing with assistance, walking with assistance, standing alone and walking alone. A yes response indicates that the patient reached a particular development milestone.
- Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE), as Appropriate According to Participant Age [ Time Frame: Baseline, Week 4, Week 13, Week 26, Week 39 and Week 52 ]The HFMSE was devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE is formed of 33 assessments. Each motor skill item is scored on a 3 point Likert scale from 0 (no response) to 2 (full response), with a total score range of 0 to 66. A higher score indicates a higher level of ability.
- Change From Baseline in Revised Upper Limb Module (RULM), as Appropriate According to Participant Age. [ Time Frame: Baseline, Week 4, Week 13, Week 26, Week 39 and Week 52 ]The RULM assesses motor performance in the upper limbs from childhood through adulthood in ambulatory and non-ambulatory individuals with SMA. 'The scale consists of an entry item to establish functional levels and 19 items covering distal to proximal movements. The entry item is a modified version of the Brooke scale, including activities ranging from no functional use of hands (score 0) to full bilateral shoulder abduction (score 6). The entry item does not contribute to the total score but serves as a functional classification of overall upper limb functional ability. Of the remaining 19 items, 18 are scored on a 3 point scoring system and 1 item is scored on a 2 point scoring system. The test is performed unilaterally using the limb preferred by the participant. The total score ranges from 0, if all the items cannot be performed, to 37, if all the activities are achieved fully without any compensation. ' Higher scores indicate higher levels of motor ability.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion
- Symptomatic SMA diagnosis based on gene mutation analysis with bi-allelic survival motor neuron 1 (SMN1) mutations (deletion or point mutations) and any copy of the survival motor neuron 2 (SMN2) gene.
- Weight ≥ 8.5 kg and ≤ 21 kg at the time of Screening Visit 2
- Naive to treatment or have discontinued an approved drug/therapy
Exclusion:
- Previous OAV101 use or previous use of any adeno-associated virus serotype 9 (AAV9) gene therapy
- BMI < 3rd percentile
- Participant with history of aspiration pneumonia or signs of aspiration
- Elevated anti-AAV9 antibody
- History of gene therapy, hematopoietic transplantation, or solid organ transplantation
- Inability to take corticosteroids
- Concomitant use of immunosuppressive therapy
- Requiring invasive ventilation, tracheostomy or awake non-invasive ventilation 9. Administration of vaccines 2 weeks prior to infusion of OAV101
- Awake hypoxemia or awake oxygen saturation level decrease
- Hepatic dysfunction
- Presence of a confirmed or suspected infection
- If previously treated with disease modifying therapy, specified washout times apply
- Documented any parental consanguinity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04851873
United States, Massachusetts | |
Novartis Investigative Site | |
Boston, Massachusetts, United States, 02115 | |
United States, Missouri | |
Novartis Investigative Site | |
Saint Louis, Missouri, United States, 63110 | |
Australia, New South Wales | |
Novartis Investigative Site | |
Randwick, New South Wales, Australia, 2031 | |
Belgium | |
Novartis Investigative Site | |
Leuven, Belgium, 3000 | |
Canada, Quebec | |
Novartis Investigative Site | |
Montreal, Quebec, Canada, H4A 3J1 | |
France | |
Novartis Investigative Site | |
Garches, France, 92380 | |
Novartis Investigative Site | |
Strasbourg, France, 67000 | |
Italy | |
Novartis Investigative Site | |
Roma, RM, Italy, 00168 | |
Portugal | |
Novartis Investigative Site | |
Lisboa, Portugal, 1600190 | |
Taiwan | |
Novartis Investigative Site | |
Kaohsiung, Taiwan, 80756 | |
Novartis Investigative Site | |
Taipei, Taiwan, 10002 | |
United Kingdom | |
Novartis Investigative Site | |
London, United Kingdom, WC1N 3JH | |
Novartis Investigative Site | |
Newcastle Upon Tyne, United Kingdom, NE1 4LP |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Documents provided by Novartis ( Novartis Pharmaceuticals ):
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT04851873 |
Other Study ID Numbers: |
COAV101A12306 2020-005995-37 ( EudraCT Number ) |
First Posted: | April 21, 2021 Key Record Dates |
Results First Posted: | January 5, 2024 |
Last Update Posted: | January 5, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/. |
URL: | https://www.clinicalstudydatarequest.com/. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Zolgensma OAV101 AVXS 101 gene therapy Muscle atrophy SBMA spinal and bulbar muscular atrophy |
spinal muscular atrophy bulbar muscular atrophy muscle function myopathy muscle wasting atrophied muscle loss of muscle strength |
Muscular Atrophy Muscular Atrophy, Spinal Atrophy Pathological Conditions, Anatomical Neuromuscular Manifestations Neurologic Manifestations |
Nervous System Diseases Spinal Cord Diseases Central Nervous System Diseases Motor Neuron Disease Neurodegenerative Diseases Neuromuscular Diseases |